Organon & Co
Change company Symbol lookup
Select an option...
OGN Organon & Co
BBWI Bath & Body Works Inc
OPI Office Properties Income Trust
DHC Diversified Healthcare Trust
GNL-A Global Net Lease Inc
PRS Prudential Financial Inc
LEN Lennar Corp
LEG Leggett & Platt Inc
LDP Cohen & Steers Limited Duration Preferred and Income Fund, Inc
LADR Ladder Capital Corp

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Organon & Co. (Organon) is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands (Organon Products). Organon has a portfolio of contraception and fertility brands, such as Nexplanon or Implanon NXT, NuvaRing, Follistim AQ, and Elonva. The Company’s Biosimilars portfolio spans immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. The Company sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. It operates its manufacturing facilities in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.

Closing Price
Day's Change
0.31 (1.59%)
B/A Size
Day's High
Day's Low

10-day average volume:

'Ride the Nvidia wave.' Wall Street says the 'undeniably pricey' stock can keep roaring

8:15 am ET May 26, 2023 (MarketWatch)

By Emily Bary

Nvidia's stock still has far more room to run despite 'monster' rally, analysts say

Even with a 160% surge in Nvidia's stock this year, analysts recommend that investors stay firmly aboard the train.

Yes, Nvidia's stock (NVDA) now trades at more than 50 times forward earnings after its monster year-to-date rally, but estimates have come up as well in the wake of Wednesday's earnings report, which brought an eye-popping outlook fueled by heavy customer spending on artificial-intelligence products.

"Everyone has been looking for ways to play AI that aren't as expensive as NVIDIA given the run this year," Bernstein's Stacy Rasgon wrote in a note to clients. "However, perhaps NVDA itself is the best way to accomplish that (while still undeniably pricey it is clearly not quite as expensive as it looked) and the narrative, backed up by actual products and sales, still has legs in our opinion."

Rasgon boosted his price target on the stock to $475 from $300. Nvidia shares closed at $379.80 Thursday after a 24% jump.

See also: If you own these stock index funds, you're already invested in AI. But there may be better strategies

Plenty of companies have talked about their various AI tailwinds, and plenty of stocks have gotten boosts from the theme in recent months. But Nvidia's ability to quickly show how that buzz has translated into real revenue seems to be the difference.

"We believe this is just the beginning of a paradigm-altering generative AI wave and, so far, it seems that NVDA is the one capturing nearly all the economics," wrote Barclays analyst Blayne Curtis, who rated the stock at overweight with a fresh $500 target, up from $275 before.

He recommended that investors "continue to ride the NVDA wave."

Read: 'Unprecedented' and 'unfathomable.' Nvidia makes jaws drop on Wall Street as stock explodes higher

Harlan Sur of JPMorgan doubled his price target, also moving to $500, while writing of "significant upside potential in shares."

Don't miss: Nvidia barrels toward rare $1 trillion valuation after putting a dollar figure on AI boost

-Emily Bary

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

May 26, 2023 08:15 ET (12:15 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.